LABORATORY NEWS
-
WORK Medical Technology Group LTD Subsidiary Obtains Manufacturing Approval For Its AI-Automated Blood Cell Morphology Analyzer
WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, today announced that its subsidiary, Hunan Saitumofei Co., Ltd., has received manufacturing approval from the Hunan Provincial Medical Products Administration for its Class II medical device, the Artificial Intelligence (“AI”)-Automated Human Blood Cell Morphology Analyzer.
- Co-Diagnostics Receives Grant Of Australian Patent Covering Co-Dx PCR Platform Technologies
- Diasorin Receives FDA 510(K) Clearance And CLIA-Waiver For Its First Assay, The 4- Plex Respiratory Panel, On The LIAISON NES Molecular Diagnostics Platform
- Next Gen Diagnostics Launches NGD Infection Prevention To Provide Real-Time Transmission Detection
- Guardant Health Japan Receives Regulatory Approval Of Guardant360® CDx Liquid Biopsy As Companion Diagnostic For Imlunestrant In Metastatic Or Recurrent Breast Cancer Previously Treated With Endocrine Therapy
ARCHIVED NEWSLETTER
- 01.06.26 -- To Fight Cancer, Gene Editing Needs To Solve Its Delivery Problem
- 12.23.25 -- Why Do So Few Cell Therapies Make The Leap From Lab To GMP?
- 12.09.25 -- What You Should Know About USP's Bioassay Updates
- 11.25.25 -- Lunit & Labcorp To Advance AI-Powered Digital Pathology Research
- 11.11.25 -- Risk-Based Analytical Method Selection In Cleaning Validation Using ASTM International Standards